At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 962 enrolled
Drug / intervention
Orforglipron +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)
In Brief
A Phase 3 clinical trial evaluating Orforglipron and Dapagliflozin for Type 2 Diabetes. Completed, enrolled 962 participants across 74 sites in 6 countries.
Detailed Summary
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesChina, Germany, Mexico, Poland, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
First PostedJan 2024
Enrollment StartJan 2024
Primary CompletionSep 2025
TodayJul 2026
First PostedJan 5, 2024
Enrollment StartJan 10, 2024
Primary CompletionSep 26, 2025
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 2.5 years ago
Interventions
Orforgliprondrug
Administered orally
Dapagliflozindrug
Administered orally